ADC Therapeutics SA (ADCT)
4.74
+0.03
(+0.64%)
USD |
NYSE |
May 02, 16:00
4.74
0.00 (0.00%)
After-Hours: 20:00
ADC Therapeutics Cash from Operations (Quarterly): -33.07M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -33.07M |
| September 30, 2023 | -34.02M |
| June 30, 2023 | -36.82M |
| March 31, 2023 | -14.77M |
| December 31, 2022 | -53.61M |
| September 30, 2022 | 2.195M |
| June 30, 2022 | -53.01M |
| March 31, 2022 | -33.88M |
| Date | Value |
|---|---|
| December 31, 2021 | -61.63M |
| September 30, 2021 | -58.59M |
| June 30, 2021 | -58.01M |
| March 31, 2021 | -55.15M |
| December 31, 2020 | -51.69M |
| September 30, 2020 | -44.29M |
| June 30, 2020 | -40.65M |
| March 31, 2020 | -32.10M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-61.63M
Minimum
Dec 2021
2.195M
Maximum
Sep 2022
-41.19M
Average
-42.47M
Median
Cash from Operations (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AC Immune SA | -17.21M |
| CRISPR Therapeutics AG | -96.07M |
| Addex Therapeutics Ltd | -0.5563M |
| NLS Pharmaceutics Ltd | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.527M |
| Cash from Financing (Quarterly) | 1.639M |
| Free Cash Flow | -121.90M |
| Free Cash Flow Per Share (Quarterly) | -0.4058 |
| Free Cash Flow to Equity (Quarterly) | -34.09M |
| Free Cash Flow to Firm (Quarterly) | -23.09M |
| Free Cash Flow Yield | -31.48% |